Cytokinetics reported $-190.07M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
Arca Biopharma USD -31.82M 2.24M Mar/2026
Bayer EUR -672M 891M Sep/2026
Biogen USD 97.5M 222M Jun/2026
Brainstorm Cell Therapeutics USD -2.13M 21K Mar/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cytokinetics USD -190.07M 8.69M Sep/2026
Eisai JPY 11.69B 6.55B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Exelixis USD 218.1M 6.04M Sep/2026
Geron USD 1.35M 18.03M Sep/2026
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Ligand Pharmaceuticals USD -28.48M 76.99M Sep/2026
Merck USD 5.07B 6.4B Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026